Drugs / Aceneuramic Acid Extended-Release
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02731690 | Apr 2016 → Jan 2018 | GNE myopathy, myopathy, distal, with rimmed vacuoles | Ultragenyx Pharmaceutical Inc | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2014-04-30 | Ultragenyx Pharmaceutical Inc | Results Ultragenyx Announces Positive Data From Phase 2 Study of Sialic Acid Extended-Release at Emerging Sciences Session of American Academy of Neurology Annual Meeting ultragenyx.com ↗
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of detailed results from a 48-week Phase 2 clinical study of sialic acid extended-release (SA-ER, UX001) tablets in 47 patients with hereditary inclusion body myopathy (HIBM; also known by its new name as GNE myopathy), a rare, progressive muscle-wasting disease. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2014-04-30 | Ultragenyx Pharmaceutical Inc | Ultragenyx Announces Positive Data From Phase 2 Study of Sialic Acid Extended-Release at Emerging Sciences Session of American Academy of Neurology Annual Meeting ultragenyx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aceneuramic Acid Extended-Release | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02731690 ↗ |
| Route | Oral | “oral tablets” NCT02731690 ↗ |